EP0742828A1 - PRODUCTION AMELIOREE DE POLY-$g(b)-HYDROXYALCANOATES DANS DES H TES PROCARYOTES TRANSFORMES - Google Patents

PRODUCTION AMELIOREE DE POLY-$g(b)-HYDROXYALCANOATES DANS DES H TES PROCARYOTES TRANSFORMES

Info

Publication number
EP0742828A1
EP0742828A1 EP95908798A EP95908798A EP0742828A1 EP 0742828 A1 EP0742828 A1 EP 0742828A1 EP 95908798 A EP95908798 A EP 95908798A EP 95908798 A EP95908798 A EP 95908798A EP 0742828 A1 EP0742828 A1 EP 0742828A1
Authority
EP
European Patent Office
Prior art keywords
vector
phb
promoter
constmct
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95908798A
Other languages
German (de)
English (en)
Inventor
John P. Kidwell
Douglas E. Dennis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Center for Innovative Technology
Original Assignee
Center for Innovative Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Center for Innovative Technology filed Critical Center for Innovative Technology
Publication of EP0742828A1 publication Critical patent/EP0742828A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C12N15/69—Increasing the copy number of the vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C12P7/625—Polyesters of hydroxy carboxylic acids

Definitions

  • the present invention relates generally to the production of carbon 15 storage polymers, and more specifically to the production of poly- ⁇ - hydroxyalkanoates such as poly- ⁇ -hydroxybutyrate.
  • PHAs Poly- ⁇ -hydroxyalkanoates
  • PHAs can be, for example, "random" copolymers wherein the copolymer comprises poly- ⁇ -hydroxybutyrate (PHB) and poly- ⁇ - hydroxyvalerate (PHN) dispersed randomly in the polymer backbone, or "semi- random,” or blocked, copolymers wherein the copolymer comprises long or short
  • PHA 25 chains of one particular PHA, for example PHB, that is separated by long or short chains of other PHAs, for example, randomly dispersed PHB and PHN.
  • PHAs are produced under certain conditions, such as where a culture is first incubated on a 3 -carbon nutrition source until the culture reaches late log phase growth, then the culture is incubated on a second carbon source
  • PHAs including PHB
  • PHB synthase are synthesized by the action of three enzymes: ⁇ -ketothiolase, acetoacetyl-CoA reductase, and PHB synthase (Oeding and Schlegel, Biochem. J. 134:239, 1973; Senior and Dawes, Biochem. J. 134:225, 1973).
  • ⁇ -ketothiolase condenses two acetyl-CoA molecules to acetoacetyl-CoA.
  • Acetoacetyl-CoA reductase reduces this compound to ⁇ -hydroxybutyryl-CoA.
  • PHB synthase typically polymerizes ⁇ -hydroxybutyryl-CoA into PHB, although other PHAs are produced under particular conditions, such as those described above.
  • the PHB biosynthetic pathway of Alcaligenes eutrophus HI 6 has been cloned into Escherichia coli (Slater et al., J. Bad. 170:4431, 1988; Schubert et al., J. Bact. 770:5837, 1988) and the DNA sequence of the pathway has been determined (Peoples and Sinskey, J. Biol. Chem. 264:15293, 1989; Peoples and Sinskey, J. Biol. Chem. 264:1529%, 1989; Janes et al., Novel Biodegradable Microbial Polymers, 175, 1990).
  • the operon consists of three genes designated phbC, phbA, and phbB, which encode PHB synthase, ⁇ - ketothiolase, and acetoacetyl-CoA reductase, respectively.
  • the transcriptional start site has been determined by deletion analysis (Janes et al., supra) and by SI nuclease mapping (Schubert et al., J. Bact. 775:168, 1991).
  • the promoter for the phb operon is very similar to the E. coli promoter recognized by ⁇ 70 (Rosenberg and Court, Ann. Rev. Genet. 73:319, 1979), and the phb operon is transcribed in E. coli.
  • the transcriptional start site is located approximately 300 bp upstream from the start of the phbC translational start site.
  • Clones that carry the phb operon on a multicopy plasmid can produce PHAs to levels as high as 80% of cell weight in media containing whey, a waste product of cheese production that contains a high concentration of lactose (Janes et al., supra).
  • the use of whey, and other low-cost food sources such as sucrose-containing food sources, has been a major stride in decreasing the overall cost of industrial scale production of PHAs.
  • Another significant expense in the industrial production of PHAs is the inclusion of an antibiotic in the growth culture of bacteria useful for PHA production. For example, in a 100,000 liter fermentor, the cost of producing about 22,000 pounds of PHB (which would be about $22,000 if no antibiotic were necessary) is increased by over $14,000 when the commonly used antibiotic chloramphenicol is added to the mixture.
  • PHAs and/or PHB would be the regulation of transcription and/or translation of the phb operon.
  • Another desirable advantage would be the provision of bacterial strains able to produce PHAs without the inclusion of an antibiotic in the growth medium.
  • the present invention provides nucleic acid vector constructs capable of regulating the transcription and/or translation of a phb operon.
  • the present invention also provides methods of using such constructs to produce PHAs, host cells transformed with such constructs, and PHA and PHB produced according to the methods of the present invention.
  • the present invention provides a nucleic acid vector construct comprising a) a promoter comprising a -35 region of a trp promoter operably linked to a -10 region of a lac promoter, and b) an operator region of the lac promoter, said promoter being operably linked to said operator region and to a phb operon.
  • the promoter is a tac promoter
  • the phb operon is derived from Alcaligenes eutrophus.
  • the vector constructs comprise a consensus Shine-Dalgamo sequence operably linked to a phbC gene of the phb operon.
  • the consensus Shine- Dalgamo sequence is added to a phb operon that is otherwise not subject to overproduction of PHA.
  • the consensus Shine-Dalgamo sequence is a lac Shine-Dalgamo sequence.
  • the consensus Shine-Dalgamo sequence may replace a native phbC Shine-Dalgamo sequence, or the consensus Shine-Dalgarno sequence may be in addition to the native phbC Shine-Dalgamo sequence.
  • the vector constructs further comprise a stabilization locus such nsparB.
  • the present invention provides vector construct having all of the essential characteristics of one, or more, of plasmids pJM9227, pJM9229, pJM9230, pJM9231, pJM9232, pJM9233, pJM9234, pJM9235, pJM9236, pJM9237, pJM9238, pJM9375, ⁇ JM9376, pJM9117 and pJM9131.
  • a vector construct having all of the essential characteristics of one of the recited plasmids retains all of the properties described herein for that plasmid.
  • the vector construct consists essentially of the nucleic acid sequence of the recited plasmid.
  • the vector constructs of the present invention have the tac promoter and the phb operon separated by a leader having a cw-acting positive regulatory element.
  • the present invention provides a runaway replicon nucleic acid vector constmct that includes an expressible phb operon.
  • a nucleic acid vector constmct has the phb operon operably linked to and positioned downstream from a) a promoter comprising a -35 region of a trp promoter operably linked to a -10 region of a lac promoter, and b) an operator region of the lac promoter, the promoter also being operably linked to the operator region.
  • the promoter is a tac promoter
  • the phb operon is derived from Alcaligenes Eutrophus and/or the runaway replicon vector construct includes a ⁇ pR promoter operably linked to a repA gene.
  • the present invention provides a method for the production of PHA, comprising: (a) introducing into a prokaryotic host cell a vector construct comprising a) a promoter comprising a -35 region of a trp promoter operably linked to a -10 region of a lac promoter, and b) an operator region of the lac promoter, the promoter being operably linked to the operator region and to a phb operon; (b) culturing the host cell in an appropriate medium; (c) adding an inducer to the medium, the inducer being capable of activating the promoter; and (d) further culturing the host cell for a time sufficient to produce PHA.
  • the inducer is IPTG and the promoter is a tac promoter, and the method, in step (a), further comprises introducing a lacN gene into the prokaryotic host cell.
  • the present invention provides a method for the production of PHA, comprising: (a) introducing into a prokaryotic host cell a runaway replicon vector constmct comprising an expressible phb operon and a ⁇ pR promoter operably linked to a repA gene, and a ⁇ cI857 gene; (b) culturing the host cell in an appropriate medium; (c) increasing the temperature of the host cell, thereby inducing the runaway replicon vector constmct; and (d) further culturing host cell for a time sufficient to produce PHA.
  • the method further comprises, during step (b), determining whether the culture of the host cells is growing rapidly or slowly; and during step (c), increasing the temperature early in a log phase of a growth cycle of the culture when the culture is fast-growing, or increasing the temperature late in a log phase of a growth cycle of the culture when the culture is slow-growing.
  • the increase in temperature is to at least 33°C when the vectors are maintained in Klebsiella and at least 36°C when the vectors are maintained in E. coli.
  • these aspects of the invention further comprise the step of isolating PHA, including PHB, from the cultured host cell.
  • the host cell is an Enterobacteriaceae host cell, further preferably an E. coli, Klebsiella or Klebsiella aerogenes.
  • the culture medium preferably does not include an antibiotic.
  • the runaway replicon vector constmct further includes a tac promoter, or other promoter inducible by a chemical inducer, such as IPTG, as described herein, and the method further comprises obtaining such overproduction of PHAs without the addition of the chemical inducer (such as IPTG).
  • the present invention provides an Enterobacteriaceae host cell, further preferably an E. coli, Klebsiella or Klebsiella aerogenes.
  • the culture medium preferably does not include an antibiotic.
  • the runaway replicon vector constmct further includes a tac promoter, or other promoter inducible by a chemical inducer, such as IPTG, as described herein, and the method further comprises obtaining such overproduction of PHAs without the addition of the chemical inducer (such
  • Enterobacteriaceae host cell containing one, or more, vector constmcts as described above.
  • the host cell is preferably an E. coli or Klebsiella.
  • the present invention provides PHA and/or PHB produced according to the methods described herein.
  • Figure 1 depicts the nucleotide sequence of a series of vector constmcts having certain transcriptional and/or translational fusions to the phb operon.
  • the nucleotide sequence denoted “a” comprises a phb promoter operably linked to a putative phbC Shine-Dalgamo sequence (denoted “SD” in the figure) (Seq. ID No. ).
  • This nucleotide sequence is present in the plasmids pJM9131 and pJM9117.
  • the nucleotide sequence denoted “b” comprises a tac promoter and a phbC Shine-Dalgamo sequence wherein there is an approximately 72 base pair leader sequence prior to the structural gene (Seq.
  • nucleotide sequence is present in the pJM9229 and pJM9236 vector constmcts.
  • the nucleotide sequence denoted “c” comprises a tac promoter and a putative phbC Shine-Dalgamo sequence wherein there is an approximately 355 base pair leader prior to the structural gene (Seq. ID No. ).
  • This nucleotide sequence is present in the pJM9232 and pJM9238 vector constmcts.
  • the nucleotide sequence denoted” comprises a tac promoter and two lac Shine-Dalgamo sequences (Seq. ID No. ).
  • This nucleotide sequence is present in the pJM9375 vector constmct.
  • the nucleotide sequence denoted “e” comprises a tac promoter, two lac Shine-Dalgamo sequences and a phbC Shine-Dalgamo sequence (Seq. ID No. ).
  • This nucleotide sequence is present in the pJM9376 vector constmct.
  • Figure 2 depicts a map of the vector construct pJM8801 (formerly known as p4A), which contains the phb operon, and the constmction of the vector constmct pJM9002, which is an 8.10 kb plasmid produced by cleaving the Eco WXllHind III phb operon-containing fragment from p4A and ligating the fragment into the same sites of pBluescript SK+.
  • Figure 2 also depicts the constmction of the pJM9131 vector construct, which is an 8.55 kb plasmid derived from pJM8801, but a kanamycin gene block is located at the Eco RI site, and ampicillin resistance has been removed by Dra I digestion.
  • Figure 2 further depicts the constmction of the pJM9226 vector constmct, which is a 3.10 kb plasmid comprising the tac promoter and a lac Shine-Dalgamo sequence ligated into the 3 kb Hind Ill-Bam HI fragment of pJM9002.
  • Figure 3 depicts a map of the vector constmct pJM8703, which is an 8.50 kb plasmid comprising the phb operon cloned into pTZ18U from United States Biochemicals. The transcription pathway starts at the Kpn I site and ends at the Eco RI site. Figure 3 also depicts the construction of the pTZ18U-4c vector constmct, which is a 7.00 kb plasmid produced by digesting pJM8703 with Sph I and Bam HI, then deleting from the Bam HI to base 835 of the published sequence followed by religation.
  • Figure 3 further depicts the constmction of the pSP72/PHB vector constmct, which is a 8.50 kb plasmid comprising the Eco Rl/ ⁇ t I fragment from pJM8703 ligated into the same sites of pSP72 (Promega).
  • Figure 3 also depicts the construction of the pJM8905 vector constmct, which is an 8.49 kb plasmid comprising a Pst l partial of Eco Rl-digested pJM8703 and ligated into pSP72, which was in turn digested with Xho I and Eco RI to provide a phb operon-containing fragment that was ligated into pGEM7Zf+.
  • Figure 3 further depicts the constmction of the pJM9117 vector construct, which is a 10.13 kb plasmid that contains the phb operon from pGEM7-PHBr cloned into the Bam H I site of pRA89, which is a 5.13 kb plasmid that is inducible above 41°, and typically has a basal copy number of 1.
  • the p JM9117 vector constmct was formerly known as pRA89/PHB/Fo.
  • Figure 4 depicts the constmction of the pJM9227 vector constmct, which is a 7.20 kb plasmid comprising the Bst Bl-Bam HI fragment from pJM8905 inserted into the Bam HI site of pJM9226 to provide a vector constmct having a tacr.phb fusion.
  • Figure 4 also depicts constmction of the pJM9228 vector construct, which is an 8.50 kb plasmid comprised of a kanamycin gene block inserted into the Eco RI site downstream of the phb operon of pJM9227 ⁇ i.e., pJM9228 is similar to pJM9227 with kanamycin resistance).
  • Figure 4 further depicts the constmction of the pJM9229 vector construct, which is a 7.80 kb plasmid comprising a 0.71 kb deletion in the bla gene of pJM9228 (i.e., the ampicillin resistance of pJM9228 was deleted).
  • Figure 5 depicts the constmction of the pJM9230 vector constmct, which is a 7.50 kb plasmid that includes the phb operon-containing Hind III-7ico RI fragment from pTZ18U-4c ligated into the Bam HI site of pJM9226.
  • Figure 5 also depicts the constmction of the pJM9231 vector construct, which comprises an 8.80 kb plasmid including a kanamycin gene block inserted into the Spe I site downstream of the phb operon in pJM9230 (i.e., pJM9231 is similar to pJM9230 with kanamycin resistance).
  • Figure 5 also depicts the constmction of the pJM9232 vector constmct, which is an 8.10 kb plasmid, including a 0.71 kb deletion in the bla gene of pJM9231 (i.e., the ampicillin resistance of pJM9231 was deleted).
  • Figure 6 depicts the constmction of the pJM9233 vector constmct, which is a 9.10 kb plasmid including the Hind III-7ic ⁇ RI fragment from pJM9227 (which contains the tacr.phb fusion), ligated into the filled-in Bam HI site of pRA89, and the constmction of the pJM9234 vector construct, which is a 9.10 kb plasmid similar to the pJM9233 vector constmct, except that the phb operon is in the reverse orientation.
  • Figure 7 depicts the constmction of the pJM9235 vector construct, which is a 9.40 kb plasmid that is similar to the pJM9233 vector constmct, except that the insert was placed in the pRA90 vector constmct, which is a 5.37 kb plasmid that is inducible at 41°, has a basal copy number of 1 and is resistant to chloramphenicol at 30 ⁇ g/ml.
  • Figure 7 also depicts the constmction of the pJM9236 vector constmct, which is a 9.40 kb plasmid that is similar to the pJM9235 vector constmct, except that the phb operon is in the reverse orientation.
  • Figure 8 depicts the constmction of the pJM9237 vector constmct, which is a 9.70 kb plasmid comprising the Hind ⁇ l-Spe l fragment from pJM9230 vector construct (which contains the tac-lea ⁇ er-phb operon fusion) ligated into the filled-in B ⁇ m HI site of ⁇ RA90, and the ⁇ JM9238 vector construct, which is a 9.70 kb plasmid similar to the pJM9237 vector constmct except that the phb operon is in the reverse orientation.
  • Figure 9 depicts the pMS421 vector constmct, which is a 5.5 kb plasmid containing the lac I gene.
  • Figure 10 depicts a series of graphs indicating the synthesis of phb operon gene products in the E. coli strains HMS174 pJM9131 (panel a), HMS174 pJM9232 pMS421 (panel b), HMS174 pJM9117 (panel c), and HMS174 pJM9238 (panel d), as a function of percentage of total protein over time.
  • Figure 11 depicts the constmction of the pJM9275 and pJM9376 vector constructs, which are 7.20 kb plasmids constructed by Exo III deletion from the Bst El site in pJM9230 to potentially remove all or a part of the native phb Shine-Dalgamo sequence, while inserting a consensus Shine-Dalgamo sequence.
  • Figure 12 depicts a series of graphs indicating the production of
  • Figure 13 depicts a pair of graphs comparing PHB yield as a percentage of dry weight in clones containing mnaway replicon vector constmcts.
  • Figure 14 depicts a pair of graphs comparing plasmid copy number in clones containing a mnaway replicon vector constmct.
  • Figure 15 depicts a graph indicating a comparison of PHB production in clones containing a multicopy tacr.phb vector construct.
  • Figure 16 depicts a graph indicating PHB production in E. coli strain HMS174 pJM9238 at different incubation temperatures.
  • Figure 17 depicts a graph indicating PHB yield in E. coli strain HMS174 pJM9238 as a function of the optical density of a culture at the time of induction.
  • Figure 18 depicts a graph indicating PHB yield in E. coli strain HMS174 pJM9238 with and without chloramphenicol.
  • Figure 19 depicts a graph indicating a comparison of PHB production in clones containing transcriptional and translational fusions (pJM9375 and pJM9376) versus a vector constmct having only a transcriptional modification (pJM9232).
  • Figure 20 depicts a pair of graphs as follows: Panel a depicts the stability of plasmid pJM9238 Klebsiella strain KC2671 over approximately 120 generations when grown in media without chloramphenicol (or other antibiotics). Panel b depicts PHB production in KC2671 pJM9238 at 31°C and 33°C.
  • Figure 21 depicts a pair of graphs as follows: Panel a depicts the production of PHB in mg/ml in KC2671 pJM9238 over time. The graph also indicates the total dry cell weight of the Klebsiella host cells including the PHB. Panel b depicts a comparison of PHB yield in KC2671 for plasmids pJM9131 and pJM9238.
  • the present invention provides nucleic acid vector constmcts suitable for introduction into an appropriate prokaryotic host where the vector constmcts provide for regulatable overproduction of PHAs, particularly PHB.
  • the vector constmcts are typically plasmids and provide for one or more of (a) regulated transcription of the phb operon due to a negatively regulated promoter, preferably comprising a -35 region of a trp promoter operably linked to a -10 region of a lac promoter, the promoter operably linked (and typically overlapping) an operator region of a lac promoter, such promoter being further operably linked to a phb operon, thereby providing multiple copies of mRNA suitable for production of PHB, (b) a mnaway replicon nucleic acid vector constmct that includes an expressible phb operon that provides multiple copies of the vector constmct upon heat induction, thereby providing numerous copies of the phb operon for
  • the present invention also provides methods of producing PHA from such high production vector constmcts, bacterial host cells transformed with such vector constmcts, and PHAs produced according to the methods of the present invention.
  • the present invention provides vector constructs that comprise strongly expressed and tightly negatively regulated promoters operably linked to the phb operon. Such promoters can be controllably “turned on” and “turned off by the introduction of an inducer or a derepressor into its host cell.
  • promoters When “turned on,” such promoters permit substantially uninterrupted transcription of a gene (or operon) operably linked thereto (and such promoters are not repressed by substances found in the host cell). When “turned off,” such promoters do not permit any substantial transcription of the gene.
  • Methods for determining whether and when such promoters are “on” and “off,” as well as the detection of gene products from the linked gene (such as mRNA, proteins or enzymes, or downstream products such as PHAs), are well known in the art, in light of the instant specification.
  • the negatively regulated promoter comprises the -35 region of the trp promoter operably linked to the -10 region of the lac promoter, and the operator region of the lac promoter (Russell and Bennett, Gene 20:231, 1982). Representative examples of such a promoter are found in Figure 1.
  • the -35 region of a promoter typically comprises an approximately 6- to 12-base sequence centered around the -35 nucleotide (plus or minus two or three nucleotides, measured from the transcription initiation site).
  • the -35 region of the trp promoter includes the nucleotide sequence TTGACA (Darnell, et al., Mol. Cell Biol, 270-85, 1986) (Seq. ID No. ).
  • the -10 region typically comprises an about a 6-base sequence centered around the -10 nucleotide (plus or minus two or three nucleotides, also measured from the transcription initiation site).
  • the lac -10 region includes the nucleotide sequence TATAAT (Darnell, supra) (Seq. ID No. ).
  • the promoter is the tac promoter, although other promoters, such as the trc promoter (Borel et al., FEBS 324:162, 1993) that also comprise operable fusions of the -35 region of the trp promoter and the -10 region of the lac promoter, are also preferred embodiments.
  • promoters are also suitable for use in the present invention, provided that such a promoter is are repressed when present in lower numbers in a cell than the given promoter's repressor molecule, and that an increase in the copy number of operators (i.e., repressor binding sites) effectively titrates out the effects of the repressor molecules, thereby inducing transcription of the desired gene.
  • a promoter is an unaltered trp promoter (Yansura and Henner, Meth. Enz. 185:54-6 , 1990).
  • a promoter is operable, i.e., repressed in the absence of inducer and expressed in the presence of inducer, can be readily determined by a person of ordinary skill in the art in light of the present specification, by screening for the presence or absence of PHA and/or PHB (for example, by examining cells under a light microscope for the presence of PHA and/or PHB), or for the presence or absence of mRNA produced from the genes of the phb operon (for example by hybridization assay).
  • initiation of transcription may be repressed by binding a repressor, such as the lad gene product, to the operator, which is located between the promoter and the phb operon.
  • a repressor such as the lad gene product
  • the operator which is located between the promoter and the phb operon.
  • a chemical inducer preferably isopropyl- ⁇ -D- thiogalactoside (IPTG)
  • IPTG isopropyl- ⁇ -D- thiogalactoside
  • Other suitable inducers will be apparent to a person having ordinary skill in the art, in light of the present specification.
  • Such inducers may include glucose- ⁇ -galactoside (lactose), glucose- ⁇ -galactoside (melibiose), and other lactose analogues such as methyl- ⁇ - galactoside and methyl- ⁇ -thiogalactoside. (Jacob and Monod, J. Mol. Biol. 3:318-356, 1961.)
  • the phb operon is the Alcaligenes eutrophus phb operon.
  • Other PHA and/or PHB producing phb operons such as those found in the prokaryotic organisms including Azotobacter, Beigerinckia, Alcaligenes, Pseudomonas, Rhizobium, Rhodospirillum and Azotobacter beijerinckii, are also acceptable and therefore are included within the scope of the present invention.
  • the present invention provides the phb operon incorporated into a mnaway replicon vector constmct.
  • a runaway replicon vector constmct is a vector constmct that can be controllably induced and that, upon induction, significantly increases its copy number in the cell.
  • the copy number of the vector construct is controlled by temperature (Nordstrom and Uhlin, Biotechnology 10:66 , 1992).
  • the repA gene which encodes a protein that is required for the initiation of plasmid replication, is under the control of the ⁇ pR promoter.
  • the ⁇ cI857 gene encodes a heat-sensitive repressor that actively inhibits transcription from the ⁇ pR promoter at low temperature, but that is inactive at high temperatures. Therefore, the incorporation of the ⁇ cI857 gene in a host cell permits repression of the ⁇ pR promoter at a low temperature.
  • low temperatures such as 30°C
  • high temperatures such as 42°C
  • synthesis of repA mRNA increases, and the vector constmct copy number is high.
  • the mnaway replicon vector constmct further comprises a tac promoter operably linked to a phb operon, to provide a tacr.phb fusion mnaway replicon vector constmct.
  • the tacr.phb fusion mnaway replicon constmct is a novel expression system in which the copy number and transcription of the phb operon are both efficiently controlled by temperature, even when IPTG (or other derepressor or inducer) is not present.
  • the copy number of the vector constmct is lower than the number of lad repressor proteins present in the cell (such number is typically about 5-10 proteins per cell (Muller-Hill et al., Proc. Natl. Acad. Sci. 59:1259, 1968).
  • the number of lad repressor molecules is sufficient to substantially repress transcription of the phb operon.
  • the number of vector constmcts surpasses the number of lad repressor molecules.
  • This system also provides the highly advantageous, and unexpected, result that the system is stable without the selective pressure of antibiotics to retain the vector constmct (although the system preferably includes a stabilization locus, discussed further below, this advantageous and unexpected result may also be found in systems without a stabilization locus).
  • the present invention provides vector constructs as described above further comprising a stabilization locus.
  • Suitable stabilization loci include parB (Gerdes, K., Bio/Technology (5:1402-1405, 1988), ccd, which appears to operate by a mechanism that involves post-segregational mortality of cells that lose a plasmid carrying the ccd locus (Gerdes, supra), the pemKJpeml system (Tsuchimoto, S. et al., J. Bact.
  • the present invention provides vector constmcts in which the phbC Shine-Dalgamo sequence (i.e., the native phbC Shine- Dalgamo sequence) is supplemented or replaced with a consensus Shine- Dalgamo sequence, preferably the lac Shine-Dalgamo sequence.
  • a Shine- Dalgamo sequence is a sequence located about 10 bases to the 5' side of the start codon (typically AUG) of an mRNA sequence. (Zubay, Biochemistry, 944-45, 1983.)
  • the consensus Shine-Dalgamo sequence comprises AGGA, although other suitable Shine-Dalgamo sequences could be easily utilized by a person having ordinary skill in the art in light of the present specification. Determination of the effectiveness of a Shine-Dalgamo sequence is also well within the skill of the art in light of the present specification, for example by screening for mRNA copy number.
  • the vector construct including the consensus Shine-Dalgamo sequence is incorporated within one or more of the vector constmcts described above.
  • the consensus Shine-Dalgamo sequence can also be advantageously used with traditional vector constmcts and the native phb promoter.
  • the present invention provides methods of producing PHB utilizing the vector constmcts described above.
  • such methods include elevating the temperature of a culture at a certain time point in order to maximize PHB production.
  • the temperature is preferably elevated at a later time in the log phase of the growth curve.
  • the temperature is preferably elevated earlier in the log phase of the growth curve. Determination of whether a culture is slow growing or fast growing will depend upon such factors as growth media, strain background, temperature, and aeration. In light of the present specification, determination of whether a culture is slow growing or fast growing and the preferred time at which to induce the culture involves routine experimentation well within the ordinary skill in the art.
  • such methods include the provision of an inducer or derepressor, such as IPTG, that induces high production of PHB from the vector constmcts. Determination of appropriate times to increase the temperature and/or add an inducer or derepressor is well within the skill of the art in light of the present specification.
  • an inducer or derepressor such as IPTG
  • the present invention provides prokaryotic host cells transformed by the vector constmcts described above.
  • Various prokaryotic host cells may be utilized within the context of the present invention.
  • preferred prokaryotic host cells should have a well-characterized genetic system, including known cloning vectors and methods of genetic manipulation. They should also preferably grow well in minimal medium, ideally to a high cell density, without any special requirements (physical or physiological).
  • Representative examples of such host cells include members of the Bacillaceae, Nocardiaceae, Streptomycetaceae, Pseudomonadaceae, Corynebacteria, and Enterobacteriaceae.
  • the host cell is able to metabolize sucrose.
  • Preferred host cells in the Family Enterobacteriaceae include Escherichia, Citrobacter, Klebsiella, Enterobacter, and Serratia, as well as Zymomonas and Flavobacterium, which are within the Enterobacteriaceae but of uncertain affiliation.
  • Particularly preferred host cells include E. coli, Klebsiella oxytoca, and Klebsiella aerogenes.
  • Preferred host cells in the Family Pseudomonaceae include P. aeruginosa.
  • the present invention provides an advantageous and unexpected result that the overproduction may be induced by a temperature increase to generally about 32°C to about 35°C, typically about 32.5°C to about 34°C, and preferably to about 33°C.
  • a temperature increase typically above 33°C, and generally above 34°C, results in smaller cell size and decreased yields.
  • prokaryotes may be readily obtained from a variety of commercial sources including, for example, the American Type Culture Collection (ATCC) (Rockville, Maryland). Alternatively, many of the above-described bacteria may be isolated from sources that are known by those of skill in the art to contain such prokaryotes, based upon techniques that are known in the art. (See Bergy's Shorter Manual of Determinative Bacteriology, Williams & Wilkins (pub.), John G. Holt (ed.), 8th edition, 1977.)
  • the PHA is preferably isolated from the host cell. Isolation may be accomplished by a variety of methods.
  • the host cells may be lysed, and PHA agglomerated, essentially as described in U.S. Application Serial No. 07/528,549.
  • lysozyme plasmids may be introduced into the host cell, and thereby utilized to enhance isolation of PHA, essentially as described in U.S. Application Serial No. 07/890,925.
  • the host cells after the host cells have reached the stationary phase of growth, they are washed once with water to remove debris. The cells are then heat sterilized, and while still hot, SDS (approximately 0.1%) and EDTA (approximately 2mM) are added, and the mixture is stirred for about one hour at a temperature of 60°C to 80°C. During this time, the cells will lyse, releasing the PHA granules. The granules are separated from cell debris by centrifugation, and then washed twice with water.
  • PHA or PHB
  • PHA purity may be calculated by determining the area under the PHA peak, and dividing it by the areas under all peaks in the chromatogram.
  • Examples 1-10, 12 and 13 are directed toward the construction of desired nucleic acid vectors.
  • Examples 11 and 14-19 are directed toward assays for the effectiveness of various aspects of the present invention.
  • Example 1 is directed toward the constmction of plasmid pJM9002 by inserting the phb operon-containing gene fragment from plasmid pJM8801 (previously designated p4A) into pBluescript SK + .
  • Example 2 is directed toward the constmction of plasmid pTZ18U-4c by deleting a segment containing the phb genes from plasmid pJM8703, which is also known as pTZ-18U-PHB.
  • Example 3 is directed toward the constmction of plasmid pJM8905 by transferring a phb operon-containing fragment from pJM8703 into pSP72 to create pSP72/PHB, followed by excision of the phb fragment from pSP72/PHB and inserting it into pGEM-7Zf + .
  • Example 4 is directed toward the constmction of plasmid pJM9131 by the insertion of kanamycin resistance into, and the deletion of ampicillin resistance from, pJM8801.
  • Example 5 is directed toward the constmction of plasmid pJM9117 by the insertion of the phb operon-containing fragment from pJM8703 into pRA89.
  • Example 6 is directed toward the constmction of plasmid pJM9226 by the deletion of the phb operon-containing fragment from pJM9002 and the insertion of the tac promoter into pJM9002.
  • Example 7 is directed to the creation of tacr.phb fusion plasmids pJM9227-pJM9229 by inserting the phb operon-containing fragment from pJM8905 into the tac promoter-containing pJM9226.
  • pJM9227 has only ampicillin resistance
  • pJM9228 has both ampicillin resistance and kanamycin resistance
  • pJM9229 has only kanamycin resistance.
  • Example 8 is directed toward the constmction of tacr.phb fusion plasmids pJM9230-pJM9232 by the insertion of the phb operon-containing fragment from pJM8703 into pJM9226.
  • pJM9230 has only ampicillin resistance
  • pJM9231 has both ampicillin and kanamycin resistance
  • pJM9232 has only kanamycin resistance.
  • pJM9230-pJM9232 differ from pJM9227-pJM9229 in that pJM9230-pJM9232 have a phbC leader of approximately 355-bases that contains a cw-acting element, while ⁇ JM9227-pJM9229 have a phbC leader of approximately 72 base pairs without such an element.
  • Example 9 is directed to the constmction of mnaway replicon tacr.phb fusion plasmids pJM9233-pJM9236 by the insertion into the runaway replicon vectors pRA89 and pRA90 the tacr.phb fusion from pJM9227.
  • pJM9233-pJM9236 have both a tac promoter and a heat inducible promoter ( ⁇ pR). These plasmids differ from each other in the orientation and precise placement of the phb gene fragment within the vector.
  • Example 10 is directed to the constmction of mnaway replicon tacr.phb fusion plasmids pJM9237 and pJM9238, which have an approximately 355-base leader.
  • Example 11 is directed to a graphic analysis of phb operon gene products, which analysis indicates that the phbC gene product (PHB synthase) is subject to post-translational regulation, and therefore is not overproduced by the plasmids constmcted pursuant to Examples 1-10.
  • PHB synthase phbC gene product
  • Examples 12 and 13 are directed to the constmction of plasmids pJM9375 and pJM9376, which were created by the addition of a consensus Shine-Dalgamo sequence operably linked to the phbC gene.
  • pJM9375 the consensus (lac) Shine-Dalgarno sequence replaced the native phbC Shine- Dalgamo sequence.
  • pJM9376 the consensus (lac) Shine-Dalgamo sequence was added to the native phbC Shine-Dalgamo sequence.
  • Example 14 is directed to a graphic comparison of PHB production in native versus tac promoter clones.
  • Example 15 is directed to a graphic comparison of PHB production in the approximately 72 base pair leader and 355 base pair leader phbC tac:: phb fusion constmcts.
  • Example 16 is directed to the optimization of PHB production at different temperatures using the heat-inducible plasmid pJM9238.
  • Example 17 is directed to the determination of the optimal cell density during the cell growth cycle for initiation of PHB production using the plasmid pJM9238.
  • Example 18 is directed to a comparison of PHB production using the plasmid pJM9238 with or without chloramphenicol.
  • Example 19 is directed to the quantitation of PHB production in plasmids pJM9375 and pJM9376, each of which contain a tac promoter and a consensus (lac) Shine-Dalgamo sequence.
  • Example 20 is directed to the determination of the stability of PHB-producing plasmids in Klebsiella.
  • Example 21 is directed to the production of PHB in Klebsiella at varying temperatures.
  • Example 22 is directed to the production of PHB in Klebsiella using plasmid pJM9238 based on fed-batch fermentation.
  • Example 22 is also directed to a comparison of PHB production using plasmid pJM9238 versus plasmid pJM9131.
  • phb operon fragment was cloned into pBluescript SK + (Stratagene) as follows.
  • plasmid pJM8801 previously designated p4A in U.S. Application Serial No. 07/890,925
  • the vector pBluescript SK + were digested with the restriction endonucleases EcoR I and Hind III (Gibco BRL) as described (Maniatis et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1982.).
  • the released fragment containing the phb genes from plasmid pJM8801 was ligated into the EcoR l-Hind III digested pBluescript SK + fragment using T4 DNA Ligase (Gibco BRL) as described in Gibco Focus Technical Bulletin 5224-1.
  • the resulting recombinant plasmid was designated pJM9002 ( Figure 2).
  • Plasmid pTZ-18U-PHB (deposited with American Type Culture Collection and assigned ATCC Deposit No. 299006, currently designated as pJM8703 ( Figure 3), was digested with Sph I (which yields a 3' overhang) and Bam HI (which creates a 5' overhang).
  • the resulting linearized fragment containing the phb genes was deleted from the Bam HI end using the procedure of Henikoff (Henikoff, S., Gene 28, 351, 1984) to approximately base 835 in the phb operon sequence previously disclosed (U.S. Application Serial No. 07/705,806).
  • the fragment was then religated using T4 DNA Ligase and the resulting circularized plasmid was designated pTZ18U-4c ( Figure 3).
  • Example 3 Construction of plasmid pJM8905
  • Plasmid pJM8905 was constmcted as follows.
  • the vector pJM8703 discussed above with respect to Figure 3, was linearized by digestion with Eco RI.
  • the linearized plasmid DNA was then partially digested with Pst I as follows. From a lOO ⁇ l digestion reaction, performed as described (Maniatis, supra), 10 ⁇ l aliquots were removed every 2.0 minutes to microplate wells containing 2 ⁇ l of 150 mM EDTA on ice. A total of 12 time-points were taken. Three microliters of 6X loading buffer (0.25% bromophenol blue, 0.25% xylene cyanol FF, 40% (w/v) sucrose) were added to each well.
  • 6X loading buffer 0.25% bromophenol blue, 0.25% xylene cyanol FF, 40% (w/v) sucrose
  • Kanamycin Resistance GENBLOCK® (Eco RI) (Pharmacia) restriction fragment was ligated into the Eco RI site of plasmid pJM8801 (p4A)
  • the phb fragment was cloned into pRA89 (Benzon Pharma A/S, Helseholmen 1, P.O. Box 1185, DK-2650 Hvidovre, Denmark; Figure 3) as follows. Plasmid p8703 (pTZ-18U-PHB) was digested with Eco RI. The resulting DNA fragment was partially digested with Pst I and the approximately 5 kb fragment containing the entire phb fragment was ligated using T4 DNA Ligase (Gibco BRL) into plasmid pSP73 (Promega) that had been digested with Eco RI and Pst I. The recombinant plasmid was transformed into E. coli strain DH5 ⁇ .
  • This plasmid was purified by the alkaline-lysis method (Maniatis et al., supra). The plasmid was then digested with Xho I and EcoR I to release the DNA fragment containing the phb operon. This fragment was ligated using T4 DNA Ligase into plasmid pGEM-7Zf l" (Promega) that had been digested with Xho I and EcoR I. The resulting plasmid was designated pGEM7f-PHB reverse. Plasmid pGEM7f-PHB reverse was digested with BamR I.
  • the released phb fragment was ligated using T4 DNA Ligase into the Bam HI site of Bam HI- digested pRA89, which had been treated with Calf Intestinal Alkaline Phosphatase (Boehringer Mannheim).
  • the resulting plasmid designated pJM9117 ( Figure 3), was introduced into E. coli strain HMS174 recAl hsdR Rif by electroporation as previously described (see U.S. Application Serial No. 08/035,433).
  • the tac promoter was cloned into the plasmid pBluescript SK + (Stratagene) as follows.
  • the vector pJM9002 (described above) was digested with the restriction endonucleases Bamli I and Hind III (Gibco BRL) as described (Maniatis et al., supra). This released the phb fragment from the pBluescript plasmid.
  • the tac promoter GENBLOCK® (Hind lll/BamH I) (Pharmacia) restriction fragment was ligated into the Hind Ul-BamH I-digested pBluescript fragment using T4 DNA Ligase (Gibco BRL) as described in Gibco BRL Focus Technical Bulletin 5224-1.
  • the recombinant plasmid was introduced into E. coli strain DH5 ⁇ by electroporation (Miller, Bacterial Electroporation, Molecular Biology Reports No. 5, Bio-Rad Laboratories, Richmond, CA, 1988) using the GENE PULSER® (Bio-Rad). Electroporation was performed as follows. An isolated colony of is. coli strain DH5 ⁇ was inoculated into a 13 x 100 mm S/P diSPo culture tube (Baxter) containing 3 ml of Luria-Bertani (LB) medium (Maniatis et al., supra).
  • LB Luria-Bertani
  • This culture was grown overnight in a Lab-Line Incubator-Shaker (Lab-Line Instruments, Inc.) at 37°C, 225 rpm. The next morning 1 ml of the culture was inoculated in 50 ml of LB medium in a baffled 250 ml Erlenmeyer flask (Wheaton). Growth of the culture was followed by withdrawing aliquots at regular time intervals and measuring the optical density at 600 nanometers using a Shimadzu UN 160 U Spectrophotometer. The culture was incubated at 37°C, 225 rpm, until the optical density at 600 nanometers reached approximately 0.5. At this time, the culture was placed on ice for 10 minutes.
  • the bacteria were again pelleted by centrifugation as before and the supernatant was aseptically aspirated.
  • Ten ml of sterile ice-cold 10% glycerol was added, the pellet was resuspended, and centrifuged as described above.
  • the supernatant was aseptically aspirated and the pellet was resuspended in a final volume of approximately 200 ⁇ l.
  • Forty microliter aliquots of this suspension were used for electroporation.
  • One microliter of plasmid D ⁇ A was added to 40 ⁇ l of the cell suspension and this mixture was added to a 0.2 cm electrode gap GENE PULSER®/7 ⁇ .
  • coli Pulser Cuvette Bio-Rad Laboratories).
  • the mixture was subjected to a pulse of 2.5KV, at 200 Ohms and 25 ⁇ farads using a GENE PULSER® (Bio-Rad Laboratories).
  • the bacterial suspension was then transferred to a sterile 13 x 100 mm culture tube containing 3 ml of LB broth.
  • the culture was incubated for 1 hour in a Lab-Line Incubator-Shaker (Lab-Line Instruments, Inc.) at 37°C, 225 rpm.
  • Transformants were selected by spreading the cells on LB agar plates containing 200 ⁇ g/ml ampicillin (Sigma). The plates were incubated at 37°C in a Fisher IsoTemp Oven Model 350D until colonies were visible.
  • Transformants were purified by picking well-isolated colonies and streaking for single colony isolation on LB agar plates containing 200 ⁇ g/ml ampicillin. Purified clones were inoculated into 3 ml of LB media containing 200 ⁇ g/ml ampicillin in 13 xlOO mm culture tubes (Baxter) and incubated overnight at 37°C in a Lab-Line Incubator-Shaker (Lab-Line Instmments, Inc.) at 200 rpm.
  • the plasmid DNA was purified by a modification of the alkaline lysis method as follows: A single colony was inoculated into a 13 x 100 mm culture tube containing 3 ml of LB broth + 200 ⁇ g/ml ampicillin and grown overnight. The culture was pipetted into two sterile 1.5 ml microfuge tubes (West Coast Scientific, Inc.) and pelleted in an Eppendorf Centrifuge 5415C microcentrifuge for two minutes. The supernatant was decanted. Each pellet was resuspended in 1 ml of ice-cold SET butter (20% sucrose, 50 mM EDTA, 50 mM Tris, pH 8.0) and centrifuged two minutes as before.
  • the supernatant was withdrawn with a pipette.
  • the cells were resuspended in a total of 150 ⁇ l of SET buffer and placed on ice.
  • Five microliters of RNase (Boehringer Mannheim) (10 ⁇ g/ml, boiled for 2 minutes) was added and the tube was vortexed.
  • Three hundred-fifty microliters of 0.2 N NaOH/1.0% SDS was added and the tube was inverted several times. The tube was incubated on ice for 20 minutes.
  • the tube was centrifuged for 5 minutes and the supernatant was decanted into a sterile 1.5 ml microfuge tube.
  • the tube was centrifuged for 5 minutes in a Eppendorf Centrifuge 5415C microcentrifuge at room temperature. The top aqueous phase was transferred to a sterile microfuge tube (West Coast Scientific, Inc.).
  • the DNA was digested with BamH I (Gibco BRL) and Hind III (Gibco BRL).
  • the restriction fragments were separated by gel electrophoresis on a 1.0% SeaPlaque (FMC BioProducts) agarose gel in TAE buffer (40 mM Tris- acetate, 1 mM EDTA, pH 8.0) using a BRL Horizon Model 58 Horizontal Gel Electrophoresis System and a BRL Model 200 Power Supply.
  • the DNA was stained by placing the gel in a 0.5 ⁇ g/ml solution of ethidium bromide for 20 minutes, followed by destaining the gel in water for 30 minutes.
  • Example 7 Construction of the multicopy tacr.phb fusion plasmids pJM9227 and pJM9229 containing a phbC leader of approximately 72 base pairs
  • Plasmid pJM8905 ( Figures 3 and 4) was digested with BstB I (New
  • T4 DNA Polymerase (Gibco BRL) was used to remove the single stranded DNA from the ends.
  • Phosphorylated BamR I linkers (New England Biolabs) were ligated to the blunt ends using T4 DNA Ligase (Gibco BRL). The resulting DNA was digested with BamR. This released a BamR I fragment that contained the phb stmctural genes but did not contain the promoter/regulatory region.
  • the DNA restriction fragments were separated by preparative gel electrophoresis on a 1.0% SeaPlaque (FMC BioProducts) agarose gel in TAE buffer using a BRL Horizon Model 58 Horizontal Gel Electrophoresis System and a BRL Model 200 Power Supply. The DNA was visualized by staining with ethidum bromide. The restriction fragment containing the phb genes was excised from the gel and purified using GENECLEAN® (BIO 101) according to the manufacturer's protocol. This fragment was then ligated into the BamH I site of plasmid pJM9226 ( Figures 2 and 4). The recombinant plasmid was then introduced into E.
  • GENECLEAN® BIO 101
  • coli strain DH5 ⁇ by electroporation and the transformants were spread on LB agar plates containing 100 ⁇ g/ml ampicillin and 1.0% glucose. The plates were incubated at 37°C in a Fisher IsoTemp Oven Model 350D until colonies were visible. White (PHB + ) colonies were picked and streaked for single isolates. Purified clones were inoculated into 3 ml of LB media containing 200 ⁇ g/ml ampicillin and grown to saturation. Plasmid DNA was prepared from the cultures as described above and digested with BamR I and Hind III to confirm the tacr.phb fusion constmct. The resulting plasmid was designated pJM9227 ( Figure 4).
  • This pJM9227 vector constmct contains the tac promoter fused 78 bp upstream of the phbC stmctural gene.
  • the native phbC Shine-Dalgamo sequence and ribosome-binding site is retained in this fusion.
  • expression of the phb genes is transcriptionally regulated by the tac promoter and translationally regulated by the native phbC Shine-Dalgamo sequence.
  • the plasmid pJM9227 was digested with EcoR I (Gibco BRL) and the 5' phosphate groups were removed using Calf Intestinal Phosphatase (New England Biolabs) to prevent self-ligation.
  • the Kanamycin Resistance GENBLOCK® (Eco RI) (Pharmacia) restriction fragment was ligated into the EcoR I site located downstream of the phb genes.
  • the resulting plasmid, pJM9228 ( Figure 4), was introduced into E. coli strain DH5 ⁇ by electroporation as previously described. The transformants were spread on LB agar plates containing 50 ⁇ g/ml kanamycin (Sigma).
  • Plasmid DNA was isolated from purified clones.
  • the plasmid-encoded ampicillin resistance gene was inactivated by Dra I (Gibco BRL) digestion to delete a 0.71 kb fragment from the bla stmctural gene, followed by religation.
  • the resulting plasmid was designated pJM9229 ( Figure 4).
  • This plasmid construct contains the tac promoter fused 78 bp upstream of thephbC stmctural gene, and results in a leader of approximately 72 bases (see Figure 1, panel b; Seq. ID No. ).
  • the native phbC Shine- Dalgamo sequence is retained in this fusion.
  • expression of the phb genes is transcriptionally regulated by the tac promoter and translationally regulated by the native phb ribosome binding sites.
  • Example 8 Construction of multicopy tacr.phb fusion plasmids pJM9230, pJM9231 and pJM9231 containing ⁇ xphbC leader of approximately 355 base pairs
  • Plasmid pJM9226 ( Figures 2 and 5) was digested with BamR I and the 5' recessed ends were filled in with T4 DNA Polymerase to form blunt ends.
  • a restriction fragment containing the phb operon was fused to the tac promoter as follows:
  • the plasmid pTZ18U-4c was digested with EcoR I and Hind III. This released a restriction fragment containing the phb structural genes and 290 bp of the upstream leader sequence.
  • the ends of the fragment were filled in using T4 DNA Polymerase (Gibco BRL). The fragment was then excised from an agarose gel and purified using GENECLEAN®.
  • the phb fragment was ligated into the plasmid containing the tac promoter fragment at the filled-in BamR I site.
  • the resulting plasmid designated pJM9230 ( Figure 5) was introduced into E. coli strain DH5 ⁇ by electroporation as previously described.
  • the transformed cells were plated on LB agar plates containing 200 ⁇ g/ml ampicillin.
  • the presence of the tac:: phb operon fusion was confirmed by screening for the PHB + phenotype (i.e., white colonies) on LB plates containing 200 ⁇ g/ml ampicillin and 1% glucose.
  • a kanamycin resistance gene was cloned into the plasmid as follows: The plasmid was digested with Spe I (New England Biolabs) and the recessed 5'-ends were filled-in with T4 DNA Polymerase to create blunt ends. The 5' recessed ends of a Kanamycin Resistance GENBLOCK® (Eco RI) (Pharmacia) restriction fragment were filled in with T4 DNA Polymerase. The Kanamycin Resistance GENBLOCK® was ligated into the filled-in Spe I site downstream of the phb operon. The recombinant plasmid, designated pJM9231 ( Figure 5), was introduced into E.
  • pJM9231 Figure 5
  • coli strain DH5 ⁇ by electroporation and transformants were selected on LB agar plates containing 50 ⁇ g/ml kanamycin.
  • Single clones were isolated and plasmid DNA isolated from these clones was purified as described above.
  • the ampicillin resistance gene (bla) was inactivated by digestion with Dra I, followed by religation, which removed a 0.71 kb fragment from the stmctural gene.
  • the resulting plasmid was designated pJM9232 ( Figure 5). This construct contains the tac promoter fused 361 bp upstream of the phbC stmctural gene, resulting in a leader of approximately 355 bases (see Figure 1, panel c; Seq. ID No. ).
  • Example 9 Construction of runaway replicon tacr.phb fusion plasmids pJM9233, pJM9234, pJM9235 and pJM9236 containing a phbC leader of approximately 72 base pairs
  • the mnaway replicon vector pRA89 (Benzon Pharma A/S,
  • restriction fragments were separated by preparative gel electrophoresis on a 1.0% SeaPlaque (FMC BioProducts) agarose gel in TAE buffer using a BRL Horizon Model 58 Horizontal Gel Electrophoresis System and a BRL Model 200 Power Supply.
  • the DNA was stained with 0.5 ⁇ g/ml ethidum bromide for 20 minutes and destained in water for 20 minutes. The bands were visualized using a UN transilluminator.
  • the restriction fragment containing the tacr.phb fusion was excised from the gel and purified using GE ⁇ ECLEA ⁇ ® (BIO 101) according to the manufacturer's protocol.
  • Phosphorylated BamR I linkers (New England Biolabs) were ligated to the ends of the fragment using T4 DNA Ligase and the DNA fragment was purified using GENECLEAN® (BIO 101). This DNA fragment was then ligated into the BamR I-digested vector pRA89. The recombinant plasmid was introduced into E.
  • Transformants were purified by picking well-isolated colonies and streaking for single colony isolation on LB agar plates containing 25 ⁇ g/ml chloramphenicol. The plates were incubated at 30°C to prevent mnaway replication. The purified isolates were screened for the presence of the phb operon by streaking the isolates onto LB agar plates containing 25 ⁇ g/ml chloramphenicol + 1.0% glucose. The plates were incubated in a Fisher IsoTemp Oven Model 350D at 37°C to induce mnaway replication. White colonies indicated the production of PHB, and thus the presence of the phb genes on the plasmid.
  • Recombinants that exhibited a PHB + phenotype at 37°C were inoculated into LB media containing 25 ⁇ g/ml chloramphenicol. The culture was incubated at 30°C for 6 hours, then 100 ⁇ l of the culture was used to inoculate 3 ml of LB media containing 50 ⁇ g/ml chloramphenicol. The cultures were incubated at 37°C overnight. Plasmid DNA was isolated from the cultures and digested with Kpn I (New England Biolabs) to determine the orientation of the tacr.phb insert.
  • the plasmid containing the tacr.phb operon fusion with the tac promoter proximal to the chloramphenicol resistance gene (cat) was designated pJM9233 ( Figure 6).
  • the plasmid containing the tacr.phb operon fusion with the tac promoter proximal to the cI857 gene was designated pJM9234 ( Figure 6).
  • These tacr.phb fusions were also cloned into the vector plasmid pRA90 (Benzon Pharma A/S, Helseholmen 1, P.O. Box 1185, DK-2650 Hvidovre, Denmark) ( Figure 7) by the same procedure.
  • the plasmid containing the tac promoter proximal to the parB locus was designated pJM9235 ( Figure 7).
  • the plasmid containing the tac promoter proximal to the chloramphenicol resistance gene (cat) was designated pJM9236 ( Figure 7).
  • these plasmid constmcts contain the tac promoter fused 78 bp upstream of the phbC stmctural gene, resulting in an approximately 72 bp leader (see Figure 1, panel b; Seq. ID No. ). These plasmids retain the native phbC Shine-Dalgamo sequence and ribosome binding site.
  • Example 10 Construction of runaway replicon tacr.phb fusion plasmids p JM9237 and pJM9238 containing a phbC leader of approximately 355 base pairs
  • the mnaway replicon vector pRA90 (Benzon Pharma A/S, Helseholmen 1, P.O. Box 1185, DK-2650 Hvidovre, Denmark) ( Figures 7 and 8) was digested with BamR I and the 5' recessed ends were filled in with T4 DNA Polymerase.
  • An EcoR l-Hind III restriction fragment from plasmid pJM9230 ( Figures 5 and 8) containing the tac promoter and the phb structural genes was gel purified as previously described and the single-stranded ends were filled using T4 DNA Polymerase. This fragment was ligated into the filled-in BamR I site of pRA90.
  • the recombinant plasmid was introduced into E.
  • coli strain XL1- Blue (Stratagene) by electroporation as previously described except the transformed cells were incubated at 30°C to allow expression of the plasmid- encoded antibiotic resistance factors.
  • the transformants were spread on LB agar plates containing 25 ⁇ g/ml chloramphenicol. The plates were incubated in a Fisher IsoTemp Oven Model 350D at 30°C to prevent mnaway replication. Transformants were purified by single colony isolation and screened for the presence of the phb operon by streaking the isolates onto LB agar plates containing 25 ⁇ g/ml chloramphenicol and 1.0% glucose. The plates were incubated at 37°C to induce mnaway replication.
  • Recombinants that exhibited a PHB + phenotype at 37°C were inoculated into LB media containing 25 ⁇ g/ml chloramphenicol. The culture was incubated at 30°C for 6 hours, then 100 ⁇ l of the culture was used to inoculate 2.5 ml of LB media containing 50 ⁇ g/ml chloramphenicol. The cultures were incubated at 37°C overnight. Plasmid DNA was isolated from the cultures and digested with Kpn I to determine the orientation of the tacr.phb insert. The plasmid containing the tacr.phb operon fusion with the tac promoter proximal to the chloramphenicol resistance gene (cat) was designated pJM9237 ( Figure 8). The plasmid containing the tacr.phb operon fusion with the tac promoter proximal to the cI857 gene was designated pJM9238 ( Figure 8).
  • these plasmid constmcts contain the tac promoter fused 361 bp upstream of the phbC stmctural gene, resulting in a leader of approximately 355 bases (see Figure 1, panel c; Seq. ID
  • the purpose of this experiment was to quantitate induction of the phb operon gene products in the tac: : phb promoter constmcts and to compare induction of the gene products to that observed in the native phb promoter clones.
  • all of the plasmids were introduced into E. coli strain HMS174 by electroporation as previously described.
  • the plasmid pMS421 obtained from G. Weinstock
  • Figure 9 was introduced into the strains containing tac:: phb fusions on multicopy plasmids by electroporation.
  • the plasmid pMS421 is a low copy number vector that confers streptomycin resistance and contains the lacN gene, which overproduces the Lac repressor protein (Muller- Hill and Gilbert, Proc. Natl. Acad. Sci. 59: 1259, 1968).
  • Five E. coli strains were used in this experiment: HMS174, HMS174 pJM9131, HMS174 pJM9232 pMS421, HMS174 pJM9117 , and HMS174 pJM9238.
  • E. coli strain HMS 174 was inoculated into 3 ml of LB medium.
  • E. coli strain HMS 174 pJM9131 was inoculated into 3 ml of LB medium containing 50 ⁇ g/ml kanamycin.
  • E. coli strain HMS 174 pJM9232 pMS421 was inoculated into 3 ml LB medium containing 50 ⁇ g/ml kanamycin and 10 ⁇ g/ml streptomycin. These cultures were shaken at 200 rpm at 37°C in a Lab-Line Incubator-Shaker (Lab-Line Instmments, Inc.) for approximately 15 hours.
  • coli strain HMS 174 pJM9238 were each inoculated into 3 ml of LB medium containing 25 ⁇ g/ml chloramphenicol. These cultures were shaken at ' 200 rpm at 30°C in a Lab-Line Orbital Environ-Shaker (Lab-Line Instruments, Inc.) for approximately 15 hours. The cultures were diluted 1:100 into 50 ml of the same media in a 250 ml baffled Erlenmeyer flask (Wheaton), except glucose was added to a final concentration of 1.0%, and the cultures were incubated at the same temperature and agitation as previously described.
  • Wheaton baffled Erlenmeyer flask
  • the growth of the culture was followed by withdrawing aliquots at regular time intervals and measuring the optical density at 600 nanometers using a Shimadzu UN 160U Spectrophotometer.
  • the phb operon was induced in E. coli strain HMS 174 pJM9232 pMS421 by the addition of IPTG to a final concentration of 10 mM at an OD600 of 2.75.
  • the phb operon was induced in E. coli strain HMS 174 pJM9117 and E. coli strain HMS 174 pJM9238 by transferring the cultures to a 41°C waterbath for 30 minutes when an OD600 of 0.7 was reached.
  • a sterile stir bar was added and the cultures were mixed at 200 rpm using a Fisher Scientific Electronic Stirrer 2008. Following the heat pulse, the cultures were incubated in a Lab-Line Incubator-Shaker (Lab-Line Instruments, Inc.) at 37°C and shaken at 200 rpm. One milliliter aliquots were withdrawn at time intervals, centrifuged in an Eppendorf Centrifuge 5415C and frozen at -70°C. These samples were subsequently analyzed by 1-D SDS-PAGE analysis. Proteins were separated by gel electrophoresis using precast Mini-PROTEA ⁇ II Ready Gels (Bio-Rad). A 12% polyacrylamide gel was used to resolve the thiolase and reductase proteins.
  • the proteins were electrophoresed for approximately 45 minutes using the Mini- PROTEA ⁇ II® Electrophoresis Cell (Bio-Rad) and BRL Model 200 Power Supply. Prestained SDS-PAGE Standards (Bio-Rad) were used as molecular weight markers to monitor protein migration through the gels during electrophoresis. The proteins were visualized by silver staining using the Bio- Rad Silver Stain Plus kit according to the manufacturer's protocol. The gels were dried between cellophane sheets using drying frames (Integrated Separation Systems). The phb gene products were quantitated as a relative percentage of total protein by densitometry using a Ultrascan XL Enhanced Laser Densitometer (LKB).
  • LLB Ultrascan XL Enhanced Laser Densitometer
  • synthase production appears to be primarily regulated at the post-transcriptional level.
  • Synthesis of thiolase is regulated at the level of transcription.
  • Synthesis of reductase appears to be a function of plasmid type or copy number, and may be regulated by a gene dosage effect.
  • Example 12 Replacement of the native phbC ribosome-binding site with the lac ribosome-binding site to create plasmids pJM9375 and pJM9376
  • the phbC Shine-Dalgamo sequence was replaced as follows.
  • a 50 ml culture of E. coli strain XL-1 Blue (Stratagene) pJM9230 was grown to saturation in LB + 50 ⁇ g/ml kanamycin in a 250 ml Erlenmeyer flask (Wheaton).
  • Plasmid pJM9230 was purified from the culture using the QIAGEN Plasmid Kit (QIAGEN Inc.) according to the manufacturer's protocol. This procedure is based on a modification of the alkaline lysis method (Bimboim and Doly, Nucl. Acids. Res. 7:1513-1522, 1979.).
  • the plasmid was digested the BstB I, which cleaves at a site approximately 30 bp upstream of the phbC stmctural gene. Small deletions were made from this site into the phbC ribosome-binding region with Exonuclease III using the double-stranded Nested Deletion Kit (Pharmacia) according to the manufacturer's protocol, with the following modifications:
  • the incubation temperature was 30°C and the digestion buffer contained 150 mM NaCl.
  • Phosphorylated BamR I linkers were ligated to the blunt ends of the deletion endpoints using T4 DNA Ligase and the DNA was introduced into E. coli strain XL-1 Blue cells by electroporation as previously described. Transformants were spread onto LB agar plates containing 200 ⁇ g/ml ampicillin and 1.0% glucose. Light-brown translucent (PHB”) colonies were picked and purified by single colony isolation. These mutants were defective in PHB production, presumably because they were unable to synthesize the phbC gene product.
  • Colonies were replica plated onto LB agar plates containing 200 ⁇ g/ml ampicillin + 1.0% glucose + 1 mM IPTG using an Accutran Replica Plater (Schleicher & Schuell). Deletion derivates that yielded large white colonies were isolated from the original selection plates and purified.
  • the plasmids were designated pJM9375 and pJM9376 ( Figure 11).
  • Example 13 Determination of the tac GeneBlock- ?AAC leader fusion joint in plasmids pJM9375 and pJM9376 by sequence analysis.
  • the precise endpoints of the Exo III deletions were determined by sequence analysis.
  • the plasmid DNA used as template was isolated from 50 ml cultures of £ coli strain HMS174 pJM9375 pMS421 and HMS174 pJM9376 pMS421 grown to saturation in LB media containing 200 ⁇ g/ml ampicillin + 10 ⁇ g/ml streptomycin.
  • the plasmid DNA was purified using a QIAGEN Plasmid Kit (QIAGEN Inc.) as previously described.
  • the DNA was sequenced using a Li-Cor DNA Sequencer Model 4000.
  • the primer used was an infrared dye- labeled M13 17-mer -20 Sequencing Primer (3'TGACCGGCAGCAAAATG5')
  • the ATG start codon was replaced with a GTG start codon. Although some mRNAs exhibit the same translational yield with ATG and GTG, the ATG codon usually results in higher translation (Gold, supra).
  • Example 14 Comparison of PHB production in native and tac promoter phb multicopy clones
  • E. coli strain HMS174 pJM9131 was inoculated into 50 ml of LB medium containing 50 ⁇ g/ml kanamycin in a 250 ml Erlenmeyer flask.
  • E. coli strain HMS 174 pJM9232 pMS421 was inoculated into 50 ml LB medium containing 50 ⁇ g/ml kanamycin and 10 ⁇ g/ml streptomycin in a 250 ml Erlenmeyer flask. These cultures were shaken at 225 rpm at 37°C in a G24 Environmental Incubator Shaker (New Brunswick Scientific) for approximately 15 hours.
  • E. coli strain HMS 174 pJM9232 and E. coli strain HMS 174 pJM9238 were each inoculated into 50 ml of LB medium containing 25 ⁇ g/ml chloramphenicol in a 250 ml Erlenmeyer flask.
  • the phb operon was induced in E. coli strain HMS 174 pJM9232 pMS421 by the addition of IPTG to a final concentration of 10 mM at an OD600 of 2.75.
  • the phb operon was induced in E. coli strain HMS 174 pJM9117 and E. coli strain HMS 174 pJM9238 by transferring the cultures to a 41°C waterbath for 30 minutes when an OD600 of 0.7 was reached.
  • the supernatant was aspirated and discarded, and the tubes containing the cell pellets were placed at -70°C for at least one hour. Uncapped screw-capped tubes containing the frozen pellets were then placed in a Labconco lyophilizer for approximately 2 hours until samples were freeze-dried.
  • Samples were then subjected to methanolysis as follows. To each tube was added 1.7 ml ACS grade methanol (Mallinckrodt), 2 ml ACS grade chloroform (Mallinckrodt), 0.3 ml concentrated sulfuric acid (added while vortexing tube) and 0.1 ml benzoic acid solution (2 mg/ml). Samples were capped tightly, placed in a heat-block adjusted to 100°C and incubated for 140 minutes. Samples were then removed from the heat block and allowed to cool to room temperature.
  • the gas chromatography system consisted of a Shimadzu GC-14A, connected to a CR-4A data processing unit, an AOC-14 autoinjector, and an AOC-1400 autosampler.
  • the carrier gas was UPC grade helium and detection was through a flame ionization detector.
  • the flow rate of the carrier was approximately 5 ml/min.
  • the column used for detection was a Supelcowax 10 column (Supelco Separation Technologies).
  • the column is a 15 meter column, 0.53 mm inner diameter, with a 1 ⁇ m thick coating. Samples (1 to 3 ⁇ l) were injected into the injection port (temperature 200°C) and carried into the column.
  • the samples were mn under temperature profile of 55°C for 5 minutes, followed by a temperature ramp of 5°C per minutes until the column temperature reached 220°C. The temperature was held at 220°C for 5 minutes, followed by a termination of the mn and cool-down for the next mn.
  • the solvent peak eluted through the detector (240°C) between 1 and 2 minutes, and the PHB peak eluted between 3 and 4 minutes.
  • Analyses were done using benzoic acid (100 ⁇ l of 2 mg/ml solution in methanolysis tubes) as an internal standard. Typically, benzoic acid eluted from the GC column approximately 5 minutes into the mn.
  • Test tubes were labeled blank, standard, and test. To each blank tube, 0.1 ml water was added. To the standard tubes, 0.1 ml of diluted Glucose Standard solution (Catalog No. 635-100) were added at concentrations of 1-20 mM. One milliliter of each culture sample to be tested was centrifuged in a Eppendorf Centrifuge 5415C microcentrifuge for two minutes to pellet the cells. To each test tube, 0.1 ml of culture supernatant was added, then 5.0 ml of o-Toluidine Reagent (Catalog No. 635-6) was added.
  • the tubes were mixed by vortexing and placed into a 100°C heat block for 10 minutes. The tubes were removed and cooled to room temperature. The contents of tubes were transferred to cuvettes and the absorbance at 635 nm was read using a Shimadzu UV 160U Spectrophotometer with the blank as reference.
  • the plasmid copy number was determined for each culture as follows. Two hundred microliters of cell suspension was centrifuged in a Eppendorf Centrifuge 5415C microcentrifuge for one minute. The supernatant was aspirated off and discarded. The cell pellet was resuspended in 50 ml of 10 mM Tris (pH 8.0), 10 mM EDTA, 100 mM NaCl, 20% sucrose, 1.5 mg/ml lysozyme (Sigma), 2 units/ml RNase. The solution was incubated for 30 minutes at 37°C. Fifty microliters of 2% SDS was added and the solution was mixed by vortexing at the maximum setting for two minutes.
  • the solution was frozen at -70°C and thawed for two cycles.
  • Five microliters of a 400 mg/ml proteinase K (BRL) stock solution was added and the tube was incubated for 30 minutes at 37°C.
  • Twenty-five microliters of loading buffer (50% glycerol, 1 mM EDTA, pH 8.0, 0.1% bromophenol blue) was added and 5-15 ⁇ l of the sample was loaded on a 0.9% agarose gel in TBE (89 mM Tris-borate, 2 mM EDTA, pH 8.0) buffer.
  • the gel was mn for three hours at 75 volts.
  • the gel was stained for 40 minutes in 1 ⁇ g/ ml ethidum bromide solution.
  • the gel was then destained for 20 minutes in water, rinsed, and destained an additional 20 minutes.
  • the gel was placed on a UN transilluminator (Fotodyne) and photographed using a Polaroid MP-4 Land Camera with Polaroid Type 665 film. The lowest F-stop was used and the shutter was opened for 45 seconds.
  • the negative was placed in fixer solution and agitated gently for approximately 30 seconds (in the dark). The negative was then washed under 65°C running water for 5 minutes and dried.
  • LLB Ultrascan XL Enhanced Laser Densitometer
  • E. coli strain HMS 174 pJM9131 and HMS 174 pJM9232 pMS421, respectively ( Figure 12, panels c and d).
  • E. coli strain HMS 174 pJM9238 also retained a higher PHB yield as a percentage of dry weight than strain HMS 174 pJM9117 throughout the post-induction period ( Figure 13, panel a). This difference was not due to a higher gene dosage for the tac promoter clone. In fact, the pJM9117 copy number was slightly higher than the pJM9238 copy number ( Figure 14, panel a).
  • tacr.phb fusions were constmcted.
  • the tac promoter was inserted 78 bp upstream of the phbC stmctural gene.
  • the tac promoter was inserted 361 bp upstream of the phbC stmctural gene.
  • Each type of fusion was cloned into a multicopy vector and runaway replicon vectors. To determine if the leader sequence contained cis- acting elements that regulated the expression of the phb genes, PHB production was quantitated in tacr.phb fusion multicopy clones containing each type of fusion.
  • the E. coli strains used in this study were HMS 174 pJM9229 pMS421 and HMS 174 pJM9232 pMS421.
  • the strains were inoculated into 50 ml of LB media containing 50 ⁇ g/ml kanamycin and 10 ⁇ g/ml streptomycin in a 250 ml baffled Erlenmeyer flask (Wheaton).
  • the culture was incubated at 200 rpm at 37 °C in a Lab-Line Orbital Environ-Shaker (Lab-Line Instmments, Inc.) for approximately 15 hours.
  • One ml of the stationary phase culture was added to 250 ml of LB media containing 1.0% glucose + 50 ⁇ g/ml kanamycin + 10 ⁇ g/ml streptomycin in a 1 liter baffled Erlenmeyer flask (Bellco) and incubated at 200 rpm at 37°C.
  • the growth of the culture was followed by withdrawing aliquots at regular time intervals and measuring the optical density at 600 nanometers using a Shimadzu UN 160U Spectrophotometer.
  • IPTG United State Biochemical Corp.
  • Samples were withdrawn at regular time intervals for GC analysis.
  • Example 17 Determination of the optimal cell density to initiate PHB production in E. coli strain HMS174 pJM9238
  • E. coli strain HMS 174 pJM9238 was induced at various cell densities as follows: The strain was inoculated into 50 ml of LB + 25 ⁇ g/ml chloramphenicol and the culture was incubated overnight at 30°C. The next morning, 250 ml of LB media containing 2% glucose and 25 ⁇ g/ml chloramphenicol in a 1 liter baffled
  • results indicate that PHB production is highest when the culture is induced at low cell density.
  • the 24 hour culture contained 5.5 mg/ml PHB (71% of dry weight).
  • PHB production was lowest when the culture was induced at mid- log phase.
  • the 24 hour culture contained only 2.2 mg/ml PHB (48% of dry weight).
  • PHB production increased as the cells entered late log phase.
  • the 24 hour culture contained 3.7 mg/ml PHB (66% of dry weight) ( Figure 17).
  • Example 18 Comparison of PHB production in E. Coli strain HMS174 pJM9238 grown in media with and without chloramphenicol
  • E. coli strain HMS 174 pJM9238 was inoculated into 50 ml of LB medium containing 25 ⁇ g/ml chloramphenicol in a 250 ml baffled Erlenmeyer flask and incubated at 30°C, 175 rpm overnight. Two 1 liter baffled Erlenmeyer flasks containing 250 ml of LB broth + 2% glucose were prepared.
  • E. coli strains HMS174 pJM9375 pMS421 and HMS174 pJM9376 pMS421 were tested for PHB production in liquid media.
  • the cultures were inoculated into 3 ml of LB media containing 200 ⁇ g/ml ampicillin and 10 ⁇ g/ml streptomycin in 16x100 mm culture tubes and grown to saturation in a Lab-Line Incubator-Shaker at 37°C with shaking at 200 rpm.
  • the cultures were diluted to an optical density at 600 nm of 0.10 into 50 ml of LB media containing 200 ⁇ g/ml ampicillin + 10 ⁇ g/ml streptomycin + 2% glucose.
  • IPTG was added to the culture to a final concentration of 10 mM. Aliquots of the cultures were withdrawn during growth for measuring optical density, dry weight analysis, and to quantitate PHB production as described above.
  • strain KC2671 The bacterial strain used in this study was Klebsiella aerogenes strain KC2671 hutC515 recA3011 A[bla]-2. Strain KC2671 was streaked onto an LB plate and strain KC2671 ⁇ MS421 was streaked onto an LB + 10 ⁇ g/ml streptomycin plate from frozen permanents. Single colonies were picked from the plates and patched onto the same medium. These were used as stock plates. Strain KC2671 was inoculated into 3 ml of LB and strain KC2671 pMS421 was inoculated into 3 ml LB + 10 ⁇ g/ml streptomycin and grown to saturation.
  • the supernatant was aspirated off, then the pellets were resuspended in 20 ml of 10% glycerol.
  • the cells were centrifuged as before, then resuspended in 10 ml of 10% glycerol in a 15 ml Falcon tube.
  • the cultures were centrifuged as before, then resuspended in 200 ⁇ l 10% glycerol. 40 ⁇ l of the cell suspension were pipetted into chilled microfuge tubes and stored at -70°C.
  • plasmid DNA was introduced into the cells by electroporation as previously described.
  • strain KC2671 pJM8238 was plated onto LB + 25 ⁇ g/ml chloramphenicol and strain KC2671 ⁇ MS421 pJM9232 was plated onto LB + 10 ⁇ g/ml streptomycin + 50 ⁇ g/ml kanamycin. The plates were incubated overnight at 30°C.
  • strain KC2671 pMS421 pJM9232 was patched onto a) LB + 10 ⁇ g/ml streptomycin + 50 ⁇ g/ml kanamycin, and b) LB + 10 ⁇ g/ml streptomycin + 50 ⁇ g/ml kanamycin + 1% glucose + 5 mM IPTG. Both plates were incubated at 30°C overnight.
  • Strain KC2671 pJM9238 was patched onto a) LB + 25 ⁇ g/ml chloramphenicol and incubated at 30°C, and b) LB + 25 ⁇ g/ml chloramphenicol + 1% glucose and incubated at 37°C.
  • the glucose-containing plates were inspected and the apparent best PHB producer of each strain was chosen.
  • the strains were then picked from the plates that did not contain glucose (that is, the best-producing cultures were then grown under conditions in which they did not make PHB and were then picked) and inoculated into 50 ml of LB containing the appropriate antibiotics.
  • the cultures were incubated for 6-8 hours at 30°C (until the cultures were in early stationary phase), then frozen permanents of each strain were made as described above and stored at -70°C.
  • Plasmid Stability Four 50 ml cultures in 250 ml Erlenmeyer flasks were started from 500 ⁇ l of frozen permanents as follows: Strain KC2671 pJMS421 pJM9232 was inoculated into a) LB medium and b) LB + 10 ⁇ g/ml streptomycin + 50 ⁇ g/ml kanamycin. Strain KC2671 pJM9238 was inoculated into a) LB medium and b) LB + 25 ⁇ g/ml chloramphenicol. The cultures were incubated at a temperature of 30°C in an Innova shaker incubator at 200 rpm. The next morning each culture was diluted into sterile 0.85% saline solution and the 10' 6 , 10 -7 , and 10 -8 dilutions were spread onto LB plates.
  • KC2671 pMS421 pJM9232 culture was pipetted into 1.5 ml microfuge tubes and centrifuged. The pellet was resuspended in 150 ⁇ l of SET buffer and stored at -20°C.
  • strain KC2671 pJM9238 45 ml of culture was centrifuged in a 50 ml Falcon tube, resuspended in 4 ml of PI buffer (QIAGEN kit), and stored at -20°C.
  • PI buffer QIAGEN kit
  • strain KC2672 pMS421 pJM9232 After 100 generations 100% (100/100) of the isolates tested from the LB culture and 100% (102/102) of the isolates tested from the LB + 10 ⁇ g/ml streptomycin + 50 ⁇ g/ml kanamycin culture retained streptomycin and kanamycin resistance. All isolates also produced PHB on plates containing glucose.
  • strain KC2671 pJM9238 after 100 generations, 99.4% (310/312) of the isolates tested from the culture grown in LB + 25 ⁇ g/ml chloramphenicol retained chloramphenicol resistance and produced PHB on plates containing glucose.
  • Klebsiella strain KC2671 pJM9238 was grown to saturation overnight in 50 ml of LB + 25 ⁇ g/ml chloramphenicol in a 250 ml Erlenmeyer baffled flask at 30°C with shaking at 175 rpm.
  • An aliquot of the culture was inoculated into 250 ml of LB media containing 2% glucose and 25 ⁇ g/ml chloramphenicol in a 1 liter Erlenmeyer baffled flask to yield an initial optical density at 600 nm of 0.10.
  • the culture was incubated at a given temperature in the range of 30°C to 40°C with shaking at 175 rpm.
  • the growth of the culture was followed by measuring the optical density at 600 nm. During exponential growth, samples of the culture were harvested for analysis of PHB production.
  • PHB could be detected in all of the cultures 2 to 4 hours after inoculation.
  • the results for two temperature induction experiments are shown in Figure 20, panel b.
  • PHB production rose from 1.054 ⁇ g/ml (0.405% of dry weight) at 3.0 hours after inoculation to 234.4 ⁇ g/ml (19.2% of dry weight) at 6.7 hours, then to 716.7 ⁇ g/ml (33.8% of dry weight) at 24 hours.
  • Klebsiella aerogenes strain KC2671 pJM9238 was tested for PHB production during fed-batch fermentation.
  • the fermentor used in this study was a B. Braun Type ES10 Biostat E 15 liter fermentor.
  • the parameters were controlled using the Micro-MFC S computer control system (B. Braun Melsungen AG) with a Hyundai Super-386C computer.
  • the strain was inoculated from a frozen permanent into 50 ml of LB medium containing 25 ⁇ g/ml chloramphenicol and grown at 31°C to saturation.
  • the cultures were inoculated into 5 liters of media containing the following components: 6 g/L Na 2 HP ⁇ 4 anhydrous, 6 g/L KH 2 P0 4 anhydrous, 5 g/L (NH 4 ) 2 S0 4 , 0.35 g/L MgS0 4 - 7H 2 O, 3 ml/L trace elements, 5 g/L yeast extract. Chloramphenicol was added to the medium at a final concentration of 25 ⁇ g/ml.
  • the feed media was composed of the following components: 33 g/L (NH 4 ) 2 S ⁇ 4 , 400 g/L glucose, 7 g/L MgS ⁇ 4 -7H 2 ⁇ , 5 ml/L trace elements, 5 g/L yeast extract.
  • the culture was incubated at 31°C to an optical density at 600 nm of approximately 3.0, at which time the temperature was shifted to 33°C. Aliquots were harvested at approximately 1 hour intervals for determination of dry weight, PHB content, and glucose concentrations. PHB content and dry weight were determined as previously described in Example 11.
  • Glucose was quantitated using the Sigma Diagnostics Glucose Assay Kit (Sigma), Procedure No. 635, p. 5, as previously described in Example 15.
  • results The results are depicted in Figure 21, panel a. PHB production was effectively repressed in KC2671 pJM9238 when the culture was grown at 31°C. Prior to thermal induction, PHB levels were at or below 0.0441 mg/ml. After the incubation temperature was increased to 33°C, PHB synthesis was rapidly induced. At the 12 hour time point (approximately 6 hours after the temperature shift to 33°C) the PHB concentration was 7.017 mg/ml, an increase of over 150-fold. At the 24 hour time point (approximately 18 hours after the temperature shift) the PHB concentration was 27.4 mg/ml, an increase of over 600-fold.
  • the rate of PHB synthesis observed in strain KC2671 pJM9238 was significantly higher than that previously observed in strain KC2671 pJM9131, as shown in Figure 21, panel b.
  • the KC2671 pJM9238 culture contained 23 mg/ml PHB, while KC2671 pJM9131 contained only 10 mg/ml PHB.

Landscapes

  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

L'invention concerne une construction de vecteurs permettant la surproduction de poly-β-hydroxyalcanoates ('PHA'), y compris le poly-β-hydroxybutyrate (PHB), dans des procaryotes, y compris Escherichia coli, en particulier. Les constructions de vecteurs permettent d'obtenir (a) une transcription régulée de l'opéron phb, fournissant ainsi de nombreuses copies de l'ARNm approprié à la production de PHA, (b) des copies multiples de la construction de vecteurs par induction de chaleur, fournissant ainsi de nombreuses copies de l'opéron phb pour la production de PHA et (c) un opéron phb modifié dans lequel la séquence Shine-Dalgarno phbC, ou le site de liaison ribosomique, est remplacé par une séquence Shine-Dalgarno de consensus, telle que la séquence Shine-Dalgarno lac. En outre, les constructions de vecteurs peuvent comprendre un locus de stabillisation. De même, des procédés de production de PHA à partir desdites constructions de vecteurs de haute production, y compris des procédés dans lesquels PHA est produit sans addition d'un agent d'induction chimique tel que IPTG ou un antibiotique, des cellules hôtes bactériennes transformées à l'aide desdites constructions de vecteur, et PHA produit selon les procédés de la présente invention sont décrits.
EP95908798A 1994-02-03 1995-02-02 PRODUCTION AMELIOREE DE POLY-$g(b)-HYDROXYALCANOATES DANS DES H TES PROCARYOTES TRANSFORMES Withdrawn EP0742828A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19212094A 1994-02-03 1994-02-03
US192120 1994-02-03
PCT/US1995/001433 WO1995021257A1 (fr) 1994-02-03 1995-02-02 PRODUCTION AMELIOREE DE POLY-β-HYDROXYALCANOATES DANS DES HÔTES PROCARYOTES TRANSFORMES

Publications (1)

Publication Number Publication Date
EP0742828A1 true EP0742828A1 (fr) 1996-11-20

Family

ID=22708350

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95908798A Withdrawn EP0742828A1 (fr) 1994-02-03 1995-02-02 PRODUCTION AMELIOREE DE POLY-$g(b)-HYDROXYALCANOATES DANS DES H TES PROCARYOTES TRANSFORMES

Country Status (2)

Country Link
EP (1) EP0742828A1 (fr)
WO (1) WO1995021257A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811272A (en) * 1996-07-26 1998-09-22 Massachusetts Institute Of Technology Method for controlling molecular weight of polyhydroxyalkanoates
WO1998036078A1 (fr) * 1997-02-13 1998-08-20 James Madison University Procede de fabrication de polyhydroxyalcanoates renfermant des monomeres de 4-hydroxybutyrate
ATE297469T1 (de) * 1997-03-03 2005-06-15 Metabolix Inc Verfahren zur polyestern-biosynthese
US6759219B2 (en) 1997-03-03 2004-07-06 Metabolix, Inc. Methods for the biosynthesis of polyesters
EP1700908B1 (fr) 1998-08-18 2016-01-06 Metabolix, Inc. Microbe transgenique pour le production de polyhydroxyalkanoate
EP3101129B1 (fr) * 2014-01-31 2020-10-28 Kaneka Corporation Micro-organisme ayant une expression ajustée du gène d'énoyl-coa hydratase r-spécifique, et procédé de fabrication de copolymère de polyhydroxyalcanoate utilisant celui-ci

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6054685A (ja) * 1983-09-02 1985-03-29 Suntory Ltd 改良発現ベクタ−およびその利用
EP0482077B1 (fr) * 1989-07-10 1998-10-21 Massachusetts Institute Of Technology Procédé de production de biopolymères à base de polyesters
US5512456A (en) * 1990-05-25 1996-04-30 James Madison University Method for the improved production and recovery of poly-β-hydroxybutyrate from transformed Escherichia coli
US5569595A (en) * 1991-09-27 1996-10-29 Center For Innovative Technology Production of poly-β-hydroxybutyrate in prokaryotic host cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9521257A1 *

Also Published As

Publication number Publication date
WO1995021257A1 (fr) 1995-08-10

Similar Documents

Publication Publication Date Title
Olsen et al. Development of broad-host-range vectors and gene banks: self-cloning of the Pseudomonas aeruginosa PAO chromosome
Zahn Overexpression of an mRNA dependent on rare codons inhibits protein synthesis and cell growth
Goldenberg et al. Role of Escherichia coli cspA promoter sequences and adaptation of translational apparatus in the cold shock response
Lin‐Chao et al. High copy number of the pUC plasmid results from a Rom/Rop‐suppressible point mutation in RNA II
Soubrier et al. pCOR: a new design of plasmid vectors for nonviral gene therapy
Gill et al. Identification of the protein encoded by the transposable element Tn 3 which is required for its transposition
US4581335A (en) Process for producing a cloned luciferase-synthesizing microorganism
Jagusztyn-Krynicka et al. Expression of Streptococcus mutans aspartate-semialdehyde dehydrogenase gene cloned into plasmid pBR322
Georgellis et al. Decay of ompA mRNA and processing of 9S RNA are immediately affected by shifts in growth rate, but in opposite manners
Garrett et al. Isolation and characterization of delta ompB strains of Escherichia coli by a general method based on gene fusions
Curiale et al. Intracistronic complementation of the tetracycline resistance membrane protein of Tn10
Bloom et al. In vitro effect of the Escherichia coli heat shock regulatory protein on expression of heat shock genes
Via et al. Transcriptional regulation of the Escherichia coli rhaT gene
Albertson et al. Effects of starvation for exogenous carbon on functional mRNA stability and rate of peptide chain elongation in Escherichia coli
WO2022151568A1 (fr) Mutant de lipase et son application
Rowe et al. The quiescent-cell expression system for protein synthesis in Escherichia coli
WO1995021257A1 (fr) PRODUCTION AMELIOREE DE POLY-β-HYDROXYALCANOATES DANS DES HÔTES PROCARYOTES TRANSFORMES
Saint et al. Physical map of the aromatic amine and m-toluate catabolic plasmid pTDN1 in Pseudomonas putida: location of a unique meta-cleavage pathway
JPH0753111B2 (ja) 条件非制御の複製挙動を持つプラスミド
Hesman et al. Cloning, characterization, and nucleotide sequence analysis of a Zymomonas mobilis phosphoglucose isomerase gene that is subject to carbon source-dependent regulation
Lewis et al. Interaction of LexA repressor with the asymmetric dinG operator and complete nucleotide sequence of the gene
Brewster et al. Tn9 and IS1 inserts in a ribosomal ribonucleic acid operon of Escherichia coli are incompletely polar
CN115605597A (zh) 用于产生赋予低至中等表达的组成型细菌启动子的方法
WO1995021260A1 (fr) Vecteurs d'acide nucleique a expression intensifiee
Furuichi et al. Physical and genetic analyses of the Inc-I alpha plasmid R64

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960903

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19981021

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000313